SOUTH SAN FRANCISCO, CA, Feb 28, 2012 (MARKETWIRE via COMTEX) --Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that
Robert I. Blum, President and Chief Executive Officer, is scheduled
to present at the following healthcare conferences during the month
of March:
Cowen & Company 32nd Annual Health Care Conference
Date: Tuesday,
March 6, 2012
Time: 8:40 a.m. Eastern Time
Location: Boston
Marriott Copley Place Hotel, Boston, Massachusetts
Roth Capital Partners 24th Annual OC Growth Conference
Date:
Tuesday, March 13, 2012
Time: 7:00 a.m. Pacific Time
Location:
Ritz Carlton Laguna Niguel, Dana Point, California
Interested parties may access the live audio webcast of this
presentation by visiting the Investor Relations section of the
Cytokinetics website at www.cytokinetics.com. The webcast replay of
the presentation will be archived on the Presentations page within
the Investor Relations section of Cytokinetics' website for two weeks
following the completion of the event.
About Cytokinetics
Cytokinetics is a clinical-stage biopharmaceutical company focused on
the discovery and development of novel small molecule therapeutics
that modulate muscle function for the potential treatment of serious
diseases and medical conditions. Cytokinetics' lead drug candidate
from its cardiac muscle contractility program, omecamtiv mecarbil, is
in clinical development for the potential treatment of heart failure.
Amgen Inc. holds an exclusive license worldwide (excluding Japan) to
develop and commercialize omecamtiv mecarbil and related compounds,
subject to Cytokinetics' specified development and commercialization
participation rights. Cytokinetics is independently developing
CK-2017357, a skeletal muscle activator, as a potential treatment for
diseases and conditions associated with aging, muscle wasting or
neuromuscular dysfunction. CK-2017357 is currently the subject of a
Phase II clinical trials program and has been granted orphan-drug
designation by the U.S. Food and Drug Administration for the
potential treatment of amyotrophic lateral sclerosis, a debilitating
disease of neuromuscular impairment in which CK-2017357 demonstrated
potentially clinically relevant pharmacodynamic effects in a Phase
IIa trial. Cytokinetics is also conducting research related to
compounds that inhibit smooth muscle contractility and which may be
useful as potential treatments for diseases and conditions associated
with excessive smooth muscle contraction, such as bronchoconstriction
associated with asthma and chronic obstructive pulmonary disorder
(COPD). All of these compounds have arisen from Cytokinetics'
research activities and are directed towards the cytoskeleton. The
cytoskeleton is a complex biological infrastructure that plays a
fundamental role within every human cell. Additional information
about Cytokinetics can be obtained at www.cytokinetics.com.
This press release contains forward-looking statements for purposes
of the Private Securities Litigation Reform Act of 1995 (the "Act").
Cytokinetics disclaims any intent or obligation to update these
forward-looking statements, and claims the protection of the Act's
safe harbor for forward-looking statements. Examples of such
statements include, but are not limited to, statements relating to
planned presentations, and the properties and potential benefits of
Cytokinetics' drug candidates and potential drug candidates. Such
statements are based on management's current expectations, but actual
results may differ materially due to various risks and uncertainties,
including, but not limited to, potential difficulties or delays in
the development, testing, regulatory approval and production of
Cytokinetics' drug candidates and potential drug candidates that
could slow or prevent clinical development or product approval,
including risks that current and past results of clinical trials or
preclinical studies may not be indicative of future clinical trials
results and that Cytokinetics' drug candidates and potential drug
candidates may have unexpected adverse side effects or inadequate
therapeutic efficacy. For further information regarding these and
other risks related to Cytokinetics' business, investors should
consult Cytokinetics' filings with the Securities and Exchange
Commission.
Contact:
Cytokinetics, Incorporated:
Jodi L. Goldstein
Manager, Corporate Communications and Marketing
(650) 624-3000
SOURCE: Cytokinetics, Inc.
